Elanco has launched Zenrelia (ilunocitinib), a once-daily tablet for pruritic dogs with atopic dermatitis, flea allergy ...

Daily moisturising may prevent infant eczema, even in low-risk babies, offering a practical approach for early skin care.

Zoetis, Inc. ZTS delivered second-quarter 2025 adjusted earnings (excluding one-time items) of $1.76 per share, which ...

ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.

In terms of drug class, immunosuppressants hold the largest market share, accounting for 42.10% in 2024. Their effectiveness ...

The JAK-inhibitor will be available to veterinarians and itchy dog owners in the United Kingdom by the end of Q3 2025.

Applying a daily emollient on infants younger than aged 9 weeks reduced the risk for atopic dermatitis by 16% at 24 months ...

A new study published in the Journal of American Medical Association showed that daily application of full-body emollients during the first 9 weeks of life significantly reduced the risk ...

Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company received approval ...

Apoquel Chewable is an FDA-approved chewable treatment in the U.S. prescribed to control itching associated with allergic ...

Investing.com -- Elanco Animal Health (NYSE: ELAN) stock rose 2.6% following the European Commission’s approval of Zenrelia, a once-daily oral treatment for canine allergic dermatitis.

Oregon Health & Science University-led research is reporting that daily full-body emollient use starting before 9 weeks of ...